PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury
OPEN BMC neurology | 10 Jun 2016
FM Hammond, DN Alexander, AJ Cutler, S D'Amico, RS Doody, W Sauve, RD Zorowitz, CS Davis, P Shin, F Ledon, C Yonan, AE Formella and J Siffert
Phase 3 trials supporting dextromethorphan/quinidine (DM/Q) use as a treatment for pseudobulbar affect (PBA) were conducted in patients with amyotrophic lateral sclerosis (ALS) or multiple sclerosis (MS). The PRISM II study provides additional DM/Q experience with PBA secondary to dementia, stroke, or traumatic brain injury (TBI).
* Data courtesy of Altmetric.com